Lerman v. Diagnostic Data, Inc.

421 A.2d 906, 1980 Del. Ch. LEXIS 438
CourtCourt of Chancery of Delaware
DecidedSeptember 23, 1980
StatusPublished
Cited by32 cases

This text of 421 A.2d 906 (Lerman v. Diagnostic Data, Inc.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lerman v. Diagnostic Data, Inc., 421 A.2d 906, 1980 Del. Ch. LEXIS 438 (Del. Ct. App. 1980).

Opinion

BROWN, Vice Chancellor.

This is an action brought by a dissident shareholder who, along with others, is attempting to wage a proxy contest so as to elect a slate of directors in opposition to those nominated for the board by management. As a result of certain amendments to the defendant corporation’s by-laws which were accomplished after incumbent management was on notice of plaintiff’s intention to wage a proxy contest, it has now become impossible for the plaintiff and his compatriots to literally comply with the amended by-laws, the requirements of which impose conditions which must be met before opposition candidates can qualify for election to the board of directors at the annual meeting. As such, the outcome of this action is necessarily governed by the scope of the Delaware Supreme Court’s ruling in Schnell v. Chris-Craft Industries, Inc., Del.Supr., 285 A.2d 437 (1971), and it therefore seems appropriate at the outset to briefly review that decision so as to establish the principles to be applied to the facts set forth hereafter.

I.

In Schnell, as it is by now well known to those involved with Delaware corporation law, it was held that inequitable action by management in amending corporate bylaws so as to change the date of the annual meeting did not become permissible simply because it was legally possible. There, with knowledge that an insurgent group wished to wage a proxy contest in an effort to replace incumbent management, the board of the defendant corporation amended the by-laws so as to enable it to move up the date of the annual meeting of shareholders. The by-laws had fixed the meeting date for the second Tuesday in January. On October 16, 1971 a committee of shareholders filed with the Securities and Exchange Commission its intention to wage a proxy battle. On October 18, 1971 Chris-Craft’s board met and did two things. First, it amended the by-laws so as to permit the annual meeting to be held at any time during the two-month period from December 1 through January 31, with the board to designate the precise date. Secondly, the board then fixed the date of the meeting for December 8, 1971. It also fixed the place of thé meeting at a comparatively remote location in upstate New York.

In this Court, Vice Chancellor (now Chancellor) Marvel concluded on the facts of record that incumbent management had “seized on a relatively new section of the Delaware Corporation Law for the purpose *908 of cutting down on the amount of time which would otherwise have been available to plaintiffs and others for the waging of a proxy battle.” Schnell v. Chris-Craft Industries, Inc., Del.Ch., 285 A.2d 430 (1971). Nonetheless, after noting that the plaintiff and his group had been contemplating their open challenge for many months prior to the sequence of events described above, but that they had chosen to talk and negotiate their position rather than to take affirmative action sooner, the Court concluded at 285 A.2d 437 that the plaintiffs

“... slow approach toward a battle designed to oust management is outweighed by management’s technical compliance with the law having to do with the calling of an annual meeting.”

Accordingly, plaintiffs’ application to preliminarily enjoin the December 8,1971 meeting, and to have the Court reset it for the second Tuesday in January 1972 in compliance with the former by-law, was refused.

On appeal, that determination was reversed by a 2 to 1 decision of the Delaware Supreme Court. It was stated for the majority as follows at 285 A.2d 439:

“In our view, those conclusions [of the then Vice Chancellor] amount to a finding that management has attempted to utilize the corporate machinery and the Delaware Law for the purpose of perpetuating itself in office; and, to that end, for the purpose of obstructing the legitimate efforts of dissident stockholders in the exercise of their rights to undertake a proxy contest against management. These are inequitable purposes, contrary to established principles of corporate democracy. The advancement by directors of the by-law date of a stockholders’ meeting, for such purposes, may not be permitted to stand. Compare Condec v. Lunkenheimer Company, Del.Ch., 230 A.2d 769 (1967).
“When the by-laws of a corporation designate the date of the annual meeting to stockholders, it is to be expected that those who intend to contest the reelection of incumbent management will gear their campaign to the by-law date. It is not to be expected that management will attempt to advance that date in order to obtain an inequitable advantage in the contest.”

In voicing his dissent to the decision of the majority, then Chief Justice Wolcott stated as follows at 285 A.2d 440:

“I do not agree with the majority of the Court in its disposition of this appeal. The plaintiff stockholders concerned in this litigation have, for a considerable period of time, sought to obtain control of the defendant corporation. These attempts took various forms.
“In view of the length of time leading up to the immediate events which caused the filing of this action, I agree with the Vice Chancellor that the application for injunctive relief came too late.”

Against this precedential backdrop, I turn to the facts of this case as established at trial.

II.

The defendant Diagnostic Data, Inc. (hereafter “DDI”) is a Delaware corporation headquartered in California. It was formerly a California corporation which was reincorporated under Delaware law. It is engaged in the development and manufacture of certain federally regulated ethical pharmaceutical products. DDI owns a patent on a drug named “Orgotein” which it believes operates to substantially alleviate, if not cure, the painful symptoms associated with rheumatoid arthritis. In fact DDI’s president, Monroe G. Smith, states that it has been established to DDI’s satisfaction that their drug will cure almost any kind of inflammation, with no side effects to the patient.

DDI has been working on the development of this drug for a number of years and it feels that it is on the verge of receiving federal approval so as to place it on the market in the United States. The drug is presently marketed on a limited basis in certain foreign countries, but as yet DDI has not been granted a license from the Food and Drug Administration. Its present business derives from selling certain horse *909 food additives. From this line it has gross sales of some $3 million, with a net profit somewhere in the vicinity of $500,000. At the same time, as a publicly held corporation having 4,446,110 shares issued and outstanding, its stock was trading over the counter at $17 per share at the time of trial.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Ted D. Kellner v. AIM ImmunoTech Inc.
Supreme Court of Delaware, 2024
Coster v. UIP Companies, Inc.
Supreme Court of Delaware, 2023
Sternlicht v. Hernandez
Court of Chancery of Delaware, 2023
Marion Coster v. UIP Companies, Inc.
Court of Chancery of Delaware, 2022
Portnoy v. Cryo-Cell International, Inc.
940 A.2d 43 (Court of Chancery of Delaware, 2008)
Accipiter Life Sciences Fund, L.P. v. Helfer
905 A.2d 115 (Court of Chancery of Delaware, 2006)
Nodak Mutual Insurance Company v. Ward County Farm Bureau
2004 ND 60 (North Dakota Supreme Court, 2004)
Harrah's Entertainment, Inc. v. JCC Holding Co.
802 A.2d 294 (Court of Chancery of Delaware, 2002)
Jewelcor Management Inc. v. Thistle Group Holdings Co.
60 Pa. D. & C.4th 391 (Philadelphia County Court of Common Pleas, 2002)
McKesson Corp. v. Derdiger
793 A.2d 385 (Court of Chancery of Delaware, 2002)
Brody v. Zaucha
697 A.2d 749 (Supreme Court of Delaware, 1997)
Kidsco Inc. v. Dinsmore
674 A.2d 483 (Court of Chancery of Delaware, 1995)
Shoen v. Amerco
885 F. Supp. 1332 (D. Nevada, 1994)
Stroud v. Grace
606 A.2d 75 (Supreme Court of Delaware, 1992)
Stahl v. Apple Bancorp, Inc.
579 A.2d 1115 (Court of Chancery of Delaware, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
421 A.2d 906, 1980 Del. Ch. LEXIS 438, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lerman-v-diagnostic-data-inc-delch-1980.